Current Report Filing (8-k)
February 08 2021 - 7:01AM
Edgar (US Regulatory)
0001638381
false
00-0000000
0001638381
2021-02-02
2021-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
February 2, 2021
INTEC PHARMA LTD.
(Exact name of registrant as specified
in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
12 Hartom St.
Har Hotzvim
|
|
|
Jerusalem, Israel
|
|
9777512
|
(Address of principal executive offices)
|
|
(Zip Code)
|
+ 972-2-586-4657
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange
on which registered
|
Ordinary Shares,
no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On February 2, 2021,
Dr. Nadav Navon, the Chief Operating Officer of Intec Pharma Ltd. (the “Company”), notified the Company of his resignation
as Chief Operating Officer of the Company, effective May 1, 2021, in order to pursue a new opportunity. Dr. Navon’s resignation
is not the result of any disagreement with the Company regarding its operations, policies or practices.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: February 8, 2021
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
2
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2023 to Sep 2024